Topic: Financials & Profitability

is this public? can be for payer or manufacturer

  • Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle

  • The Drugs at the Heart of Our Pricing Crisis

  • Bottom-Up Pricing Estimate for P-quad

  • Modeling P-quad

  • Who Is Sowing Seeds of Confusion About The QALY?

  • Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

    Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection